KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.Lancet OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40516558无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.EBioMedicinePMID 40517603PMC122786232025-Jul0.98未发现恶性肿瘤人群证据。部分完成
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.Lancet Oncol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 multi panel km;Figure 3:AI 判定为 other。PMID 40517778PMC76179722025-Jul0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.J Alzheimers Dis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40518812PMC124643532025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40523368无 PMCID2025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40523369无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study.J Hum Hypertens已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:森林图/亚组分析图;Fig. 5:AI 判定为 other;另有 1 张未列出。PMID 40527906PMC123432972025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.ESMO OpenPMID 40540760PMC122213532025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.Lancet OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40541214无 PMCID2025-Jul0.95The study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result. However, the primary endpoint is a complete response rate (a binary outcome at a fixed time point), which does not qualify as a time-to-event efficacy endpoint per the protocol's definition (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).无 KM 图
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40552968无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial.J Cosmet Dermatol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:森林图/亚组分析图。PMID 40586136PMC122075672025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.J Gynecol OncolPMID 40590325PMC122263152025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.J Gynecol OncolPMID 40590326PMC122263272025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.J Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图。PMID 40590327PMC122263172025-Jul0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.JCO Precis Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:森林图/亚组分析图;Figure 3.:非 KM 图;Figure 4.:森林图/亚组分析图;Figure 5.:非 KM 图。PMID 40591902PMC127131492025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.JCO Precis OncolPMID 40601896PMC122331772025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit: a multiarm multistage adaptive randomized controlled clinical trial (DEMEL).Intensive Care Med已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 40608082PMC122838182025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort.Eur J Neurol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40631687PMC122390382025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.JCO Precis OncolPMID 40632974PMC122611102025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial.Clin Transl Sci已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 forest plot;FIGURE 3:森林图/亚组分析图。PMID 40657894PMC122574982025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial.Circ Cardiovasc IntervPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40663622无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Donanemab exposure-response in early symptomatic Alzheimer's disease.Alzheimers DementPMID 40667684PMC122650202025-Jul0.98未发现恶性肿瘤人群证据。已完成
Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia.Alzheimers Dement已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。PMID 40717666PMC123016952025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.Pediatr Pulmonol已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。PMID 40728026PMC123057532025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial.Health Technol Assess疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40755226PMC123762062025-Jul0.90The record does not meet the time-to-event efficacy endpoint criterion required for inclusion in the KM digitization cohort.无 KM 图
Effects of an Afrocentric Sexual Health Education Curriculum for Medical, Nursing, and Midwifery Students in Tanzania: A Single-Blinded Randomized Controlled Phase 3 Trial.Arch Sex Behav已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。PMID 40789797PMC124574732025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.Eur Respir J入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40210412PMC122568062025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Outcomes of posterior lamellar tarsal rotation vs bilamellar tarsal rotation for trachomatous trichiasis.PLoS Negl Trop Dis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40737343PMC123310572025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.Nephrol Dial TransplantPMID 39817409PMC122076042025-Jun-300.98未发现恶性肿瘤人群证据。已完成
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40562047无 PMCID2025-Jun-280.98未发现恶性肿瘤人群证据。无 KM 图
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40562048无 PMCID2025-Jun-280.98未发现恶性肿瘤人群证据。无 KM 图
Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study.J Gastrointest Cancer已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图。PMID 40571773PMC122026232025-Jun-270.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.Sci Adv入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40577471PMC122041552025-Jun-270.98未发现恶性肿瘤人群证据。无 KM 图
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40162661无 PMCID2025-Jun-260.98未发现恶性肿瘤人群证据。无 KM 图
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.N Engl J MedPMID 40444708PMC121978372025-Jun-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial.Open HeartPMID 40571489PMC122071662025-Jun-260.98未发现恶性肿瘤人群证据。已完成
[Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial].Zhonghua Wei Chang Wai Ke Za ZhiPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40550657无 PMCID2025-Jun-250.95The study is an oncology, human, randomized, Phase III trial with original results. However, it compares two surgical techniques (side-to-end vs. end-to-end anastomosis) and does not include a drug-containing intervention. Furthermore, the primary endpoint is the LARS score at 12 months, which is a patient-reported functional outcome, not a time-to-event efficacy endpoint such as OS, PFS, DFS, or any Kaplan-Meier/HR analysis. Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort.无 KM 图
Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.JAMA已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure.:AI 判定为 flow diagram。PMID 40294395PMC120387112025-Jun-240.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.Circulation已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:瀑布图。PMID 40391436PMC121806922025-Jun-240.98未发现恶性肿瘤人群证据。无 KM 图
The distal nephron biomarkers associate with diabetic kidney disease progression.JCI Insight已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 40548378PMC122209532025-Jun-230.98未发现恶性肿瘤人群证据。无 KM 图
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small-cell lung cancer better preserves white matter networks compared to conventional PCI.Neuro Oncol已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。PMID 39718983PMC121873682025-Jun-210.70The study is an oncology, human, randomized, phase 3 trial with original results. However, it does not meet the inclusion criteria because it lacks a drug-containing intervention (comparing radiation techniques) and does not report a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) for Kaplan-Meier digitization. The endpoints are neurocognitive and neuroimaging outcomes.无 KM 图
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40473448无 PMCID2025-Jun-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.Lancet已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:瀑布图;Figure 3:AI 判定为 other。PMID 40473450PMC122854202025-Jun-210.95The study is a Phase 3, randomized, placebo-controlled trial of a drug in an oncology population, but its primary endpoint is objective response rate, not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) with Kaplan-Meier or HR reporting. Therefore, it does not meet the cohort's core requirement for a time-to-event efficacy endpoint.无 KM 图
Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.Chin Med J (Engl)PMID 39385327PMC121808412025-Jun-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.Br J Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 39862230无 PMCID2025-Jun-200.98未发现恶性肿瘤人群证据。无 KM 图
Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40112876无 PMCID2025-Jun-200.98未发现恶性肿瘤人群证据。无 KM 图
Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.J Clin OncolPMID 40367400PMC121701552025-Jun-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].Zhonghua Gan Zang Bing Za ZhiPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40660986PMC128618502025-Jun-200.98未发现恶性肿瘤人群证据。无 KM 图
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40202593无 PMCID2025-Jun-190.98未发现恶性肿瘤人群证据。无 KM 图
Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial.RMD Open入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 40537275PMC121821062025-Jun-190.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图